Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee
reported one patient with 3-methylglutaric aciduria displayed thinning of the corpus callosum, enlarged lateral and third ventricles, and basal ganglia atrophy in cranial MRI
GLP-1 agonists initially faced coverage challenges that have progressively improved
In this blog post we examine the overall market context from the top-selling drugs of 2025 H1 to the surge of dealmaking in obesity therapeutics and then drill into why Eli Lilly, with its GLP-1 pipeline and commercialization strategy, has emerged as the biggest beneficiary of this trend
Maiti A, MBBS, DiNardo CD, MD, MSCE, Rausch CR, PharmD, Pemmaraju N, MD, Garcia-Manero G, MD, Ohanian M, DO, Daver N, MD, Issa GC, MD, Borthakur G, MD, Ravandi F, MBBS, Alvarado Y, MD, Kadia TM, MD, Short NJ, MD, Jabbour EJ, MD, Montalban-Bravo G, MD, Jain N, MD, Kornblau SM, MD, Masarova L, MD, Wierda WG, Sasaki K, MD, PhD, Takahashi K, MD, PhD, Yilmaz M, MD, Burger JA, MD, PhD, Estrov ZE, MD, Verstovsek S, MD, PhD, Andreeff M , MD, PhD, Bose P, MD, Ferrajoli A, MD, Thompson PA, Montalbano K, Vaughan K, RN, Bivins CA, RN, Pierce SA, BSN, BA, Qiao W, PhD, Ning J, Welch J, PhD MD, Kantarjian H, MD, Konopleva M, MD, PhD
I lost 2 inches in one month of daily intake Great product for genuine inch loss If you really want to see toned body have Nutrikonas L-Carnitine
